Ignite Creation Date:
2024-05-05 @ 11:47 AM
Last Modification Date:
2024-10-26 @ 9:13 AM
Study NCT ID:
NCT00135343
Status:
COMPLETED
Last Update Posted:
2011-04-14
First Post:
2005-08-25
Brief Title:
A Pilot Study of AtazanavirRitonavirEfavirenz as a Nucleoside Sparing Regimen
Sponsor:
Bristol-Myers Squibb
Organization:
Bristol-Myers Squibb
Study Overview
Official Title:
A Pilot Study of AtazanavirRitonavirEfavirenz as a Nucleoside Sparing Regimen
Status:
COMPLETED
Status Verified Date:
2008-07
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The purpose of this study is to evaluate the safety and efficacy of a novel nucleoside sparing regimen containing atazanavir ritonavir and efavirenz using two different doses of atazanavir
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None